Jet Capital Investors’s AstraZeneca AZN Stock Holding History

Jet Capital Investors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-200,000	Closed	-$14.3M	–	50
2014 Q3	$14.3M	Sell	200,000 -375,000	-65%	-$27.4M	0.53%	34
2014 Q2	$42.7M	Buy	+575,000	New	+$41.6M	1.92%	15

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Jet Capital Investors's AZN Position: Q4 2014 in Review

Jet Capital Investors sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 200,000 shares — an estimated $14.3M sold.

Jet Capital Investors first reported a position in AZN in Q2 2014 and held it in 2 quarters. The position peaked at $42.7M in Q2 2014. 404 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

Jet Capital Investors reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
Jet Capital Investors sold 200,000 AstraZeneca shares in Q4 2014, an estimated $14.3M.
Jet Capital Investors first reported a position in AstraZeneca in Q2 2014 and held it in 2 quarters.
Jet Capital Investors's AstraZeneca position peaked at $42.7M in Q2 2014.
404 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on Jet Capital Investors's 13F filing for Q4 2014, filed 17 Feb 2015.